{"url_path":"/sec/anip/10-k/2026/item-9b","section_key":"item-9b","section_title":"Item 9B Other Information","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-02-27","source_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000014-index.html","accession_number":"0001023024-26-000014","cik":"0001023024","ticker":"ANIP","issuer_name":"ANI PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1023024/0001023024-26-000014-index.html","primary_entity_key":"0001023024","primary_entity_name":"ANI PHARMACEUTICALS INC"},"word_count":87,"has_tables":true,"body_markdown":"Item 9B. Other Information\n\nTrading Arrangements\n\nDuring the fiscal quarter ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) entered into, adopted, modified (as to the amount, price or timing of trades), or terminated (i) contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in a \"Rule 10b5-1 trading arrangement\" or \"non-Rule 10b5-1 trading arrangement,\" as those terms are defined in Regulation S-K, Item 408(a)."}